Does FDA’s Rolling Review Of COMP360 Psilocybin Depression Therapy Change The Bull Case For COMPASS Pathways (CMPS)?
In April 2026, COMPASS Pathways announced that the FDA granted a rolling NDA review for its synthetic psilocybin…
AtaiBeckley’s BPL-003 Depression Data Sharpen Clinical Path And Investor Focus
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. AtaiBeckley…
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals – Endpoints News
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsCompass Pathways Successfully Achieves Primary…
Clinical Trials Provide Hope For A New Treatment Path For Treatment Resistant Depression » TwistedSifter
Pexels Treatment-resistant depression (TRD) is surprisingly prevalent, with 48% suffering from this form of depressive disorder, with clear…
Report: Nitrous oxide found effective as major depression treatment
Nov. 30 (UPI) — Results of a new study show that patients with major depressive order who have…
DNA test boosts recovery in treatment-resistant depression
A major new meta-analysis shows that a DNA test guiding antidepressant choice boosts recovery odds in treatment-resistant depression,…